Healthcare Companies Positioned in Major Markets
HENDERSON, NV / ACCESSWIRE / February 15, 2019 / Pain relief medicines are a massive market 30 billion doses of which are consumed each year in the US alone. Opioids like codeine and hydrocodone are also commonly used to in the US but these cause a completely different problem: addiction, which caused more than 20,000 overdoses in 2015.
BioRestorative Therapies, Inc. (BRTX) is one of the most intriguing in this space. Their BRTX-100 has shown positive results in both preclinical animal and human studies. BioRestorative has an open IND (Investigational New Drug) and has agreed with the FDA on a Phase 2 trial protocol that is targeted to start Q1 of 2019 (this quarter). Since there could be news any day, it'd be wise to start your research immediately.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Clearside Biomedical, Inc. (CLSD), Avinger, Inc. (AVGR), Aphria, Inc. (NYSE: APHA), and Invacare Corporation (IVC).
The Global Chronic Low Back Pain Market is relied upon to achieve an estimation of US$ 9.19 billion by 2025, developing at a CAGR of 5.1% amid the forecast time frame of 2017-2025. BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.235M, Share Price: $0.6995), a life sciences company focused on stem cell-based therapies as we mentioned above, is working on their BRTX-100 solution.
That's not the only major market BRTX is positioned in. The company is developing a therapy fight the obesity epidemic. Their "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
_____
Clearside Biomedical, Inc. (CLSD) (Market Cap: $49.638M, Share Price: $1.55), a biopharmaceutical company developing treatments for serious eye diseases, announced that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly "suprachoroidal CLS-TA") in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center.
_____
Avinger, Inc. (AVGR) (Market Cap: $10.087M, Share Price: $0.43), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its Pantheris® SV (Small Vessel) image-guided atherectomy system was featured in a live case transmission at Leipzig Interventional Course (LINC) 2019, a leading global forum for new methods and technology in the field of vascular medicine held annually in Leipzig, Germany.
_____
Aphria, Inc. (APHA) (Market Cap: $2.256B, Share Price: $9.09) announced earlier this week that its Board of Directors decided, after much anticipation, to reject the hostile bid by Green Growth Brands Inc to acquire all of the outstanding common shares of the Company including any Common Shares that may become issued and outstanding after January 22, 2019, but prior to the expiry of the hostile bid upon the exercise, conversion or exchange of options, warrants, debentures or other securities of the Company exercisable or convertible into Common Shares, other than Common Shares owned by GGB or its affiliates, in exchange for 1.5714 shares of GGB.
_____
Invacare Corporation (IVC) (Market Cap: $285.861M, Share Price: $8.61) announced their 4th quarter numbers, The Elyria, Ohio-based company said it had a loss of 4 cents per share. Losses adjusted for non-recurring gains, were 16 cents per share. The wheelchair, crutches and motorized scooter company posted revenue of $244.6 million in the period. For the year, the company reported that its loss narrowed to $43.9 million, or $1.33 per share. Revenue was reported as $972.3 million.
Legal Disclaimer:
This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: Regal Consulting
View source version on accesswire.com:
https://www.accesswire.com/535478/Healthcare-Companies-Positioned-in-Major-Markets
